[go: up one dir, main page]

MX2019013970A - Composiciones farmaceuticas de liberacion sostenida retardada. - Google Patents

Composiciones farmaceuticas de liberacion sostenida retardada.

Info

Publication number
MX2019013970A
MX2019013970A MX2019013970A MX2019013970A MX2019013970A MX 2019013970 A MX2019013970 A MX 2019013970A MX 2019013970 A MX2019013970 A MX 2019013970A MX 2019013970 A MX2019013970 A MX 2019013970A MX 2019013970 A MX2019013970 A MX 2019013970A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
sustained release
release pharmaceutical
delayed sustained
delayed
Prior art date
Application number
MX2019013970A
Other languages
English (en)
Other versions
MX390677B (es
Inventor
Han Park Jae
Chung Lai Tsz
Brian Lippold Alexander
Sue Walker Rebecca
Original Assignee
SpecGx LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SpecGx LLC filed Critical SpecGx LLC
Publication of MX2019013970A publication Critical patent/MX2019013970A/es
Publication of MX390677B publication Critical patent/MX390677B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones farmacéuticas de liberación sostenida retardada que proporcionan efectos terapéuticos en períodos de tiempo prolongados (es decir, 14-16 horas).
MX2019013970A 2017-06-14 2018-06-07 Composiciones farmaceuticas de liberacion sostenida retardada con anfetamina MX390677B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762519351P 2017-06-14 2017-06-14
PCT/US2018/036424 WO2018231619A1 (en) 2017-06-14 2018-06-07 Delayed sustained release pharmaceutical compositions

Publications (2)

Publication Number Publication Date
MX2019013970A true MX2019013970A (es) 2020-02-10
MX390677B MX390677B (es) 2025-03-21

Family

ID=64655979

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013970A MX390677B (es) 2017-06-14 2018-06-07 Composiciones farmaceuticas de liberacion sostenida retardada con anfetamina

Country Status (12)

Country Link
US (1) US11033508B2 (es)
EP (1) EP3638211B1 (es)
JP (1) JP6990719B2 (es)
AU (1) AU2018286535B2 (es)
BR (1) BR112019024708A2 (es)
CA (1) CA3064891A1 (es)
DK (1) DK3638211T3 (es)
ES (1) ES2967488T3 (es)
HU (1) HUE065294T2 (es)
MX (1) MX390677B (es)
PL (1) PL3638211T3 (es)
WO (1) WO2018231619A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019024708A2 (pt) 2017-06-14 2020-06-09 SpecGx LLC composições farmacêuticas de liberação prolongada retardada
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0886519A1 (en) 1996-11-01 1998-12-30 Ilex Oncology, Inc. Sustained release formulation containing dfmo
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
US8906413B2 (en) 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
WO2006138227A1 (en) * 2005-06-16 2006-12-28 Forest Laboratories, Inc. Modified and immediate release memantine bead formulation
US8846100B2 (en) 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
MX2008014455A (es) 2006-05-12 2008-11-27 Shire Llc Sistema de suministro de farmaco de dosis controlada.
CN103120653B (zh) 2007-04-04 2015-09-30 希格默伊德药业有限公司 一种口服药物组合物
ES2681952T3 (es) 2013-03-15 2018-09-17 SpecGx LLC Forma farmacéutica sólida disuasoria del abuso de liberación inmediata con puntaje funcional
BR112019024708A2 (pt) 2017-06-14 2020-06-09 SpecGx LLC composições farmacêuticas de liberação prolongada retardada

Also Published As

Publication number Publication date
DK3638211T3 (da) 2024-01-22
EP3638211A1 (en) 2020-04-22
CA3064891A1 (en) 2018-12-20
JP2020523290A (ja) 2020-08-06
US20180360764A1 (en) 2018-12-20
EP3638211A4 (en) 2021-03-24
EP3638211B1 (en) 2023-11-29
MX390677B (es) 2025-03-21
WO2018231619A1 (en) 2018-12-20
AU2018286535B2 (en) 2023-08-17
US11033508B2 (en) 2021-06-15
BR112019024708A2 (pt) 2020-06-09
HUE065294T2 (hu) 2024-05-28
ES2967488T3 (es) 2024-04-30
PL3638211T3 (pl) 2024-04-15
JP6990719B2 (ja) 2022-01-12
AU2018286535A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
ZA201906822B (en) Indole ahr inhibitors and uses thereof
MX391159B (es) Proteínas de unión al antígeno anti-tigit y métodos para usarlas
GEP20217239B (en) Pharmaceutical composition
MX380250B (es) Compuestos farmacéuticos inhibidores de cinasa chk-1.
MX2019014041A (es) Inhibidores pirazolicos de magl.
MX381487B (es) Ciertos inhibidores de la proteina quinasa.
MX373549B (es) Derivado de pirazol amida.
MX2018004674A (es) Moduladores de interacción de sestrina-gator2 y sus usos.
MX389724B (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
AR109376A1 (es) FORMULACIONES DE g-HIDROXIBUTIRATO DE LIBERACIÓN MODIFICADA
MX2018007390A (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
GEP20217240B (en) Pharmaceutical composition
ECSP18018793A (es) Compuestos útiles para inhibir ror-gamma-t
EP3675860A4 (en) SUBSTITUTED PYRIMIDINS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC PROCEDURES THEREFORE
EA201792262A1 (ru) Пироглутамат вортиоксетина
MX2017013072A (es) Inhibidores de grelina o-aciltransferasa.
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF
EA202090732A1 (ru) Составы для трансдермального введения
DK3403674T3 (da) Farmaceutiske sammensætninger til behandling af smerte
MX385910B (es) Composiciones de fragancia que comprenden ciclohexanoato de etilo.
MX376741B (es) Composición farmaceútica de sulfonamida
MX2019013970A (es) Composiciones farmaceuticas de liberacion sostenida retardada.